GSK receives approval for Incruse™ Ellipta® (umeclidinium) in the US for the treatment of COPD

GlaxoSmithKline plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Incruse™ Ellipta® (umeclidinium) as an anticholinergic indicated for the long-term, once-daily, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.
Source: GSK news - Category: Pharmaceuticals Source Type: news